Background: Off-pump coronary artery bypass (OPCAB) surgery carries a high risk for haemodynamic instability and perioperative organ injury. Favourable haemodynamic effects and organ-protective properties could render xenon an attractive anaesthetic for OPCAB surgery. The primary aim of this study was to assess whether xenon anaesthesia for OPCAB surgery is non-inferior to sevoflurane anaesthesia with regard to intraoperative vasopressor requirements. Methods: Forty-two patients undergoing elective OPCAB surgery were enrolled in this prospective, single-blind, randomized controlled pilot trial. Patients were randomized to either xenon (50-60 vol%) or sevoflurane (1.1-1.4 vol%) anaesthesia. Primary outcome was intraoperative noradrenaline requirements necessary to achieve predefined haemodynamic goals. Secondary outcomes included safety variables such as the occurrence of adverse events (intraoperatively and during a 6-month follow-up after surgery) and the perioperative cardiorespiratory and inflammatory profile. Results: Baseline and intraoperative data did not differ between groups. Xenon was non-inferior to sevoflurane, as xenon patients required significantly less noradrenaline intraoperatively to achieve the predefined haemodynamic goals {geometric mean 428 [95% confidence interval (CI) 312, 588] vs 1702 [1267, 2285] µg, P<0.0001}. No differences were found for safety. Significantly more sevoflurane patients developed postoperative delirium (POD) (hazard ratio 4.2, P=0.044). The average arterial pressure was lower in the sevoflurane group {median75 [interquartile range (IQR) 6] vs 72 [4] mmHg, P=0.002}. No differences were found for other haemodynamic parameters, the respiratory profile and the perioperative release of inflammatory cytokines, troponin T, serum protein S-100β and erythropoietin. Conclusions: Compared with sevoflurane, xenon anaesthesia allows a significant reduction in vasopressor administration in OPCAB surgery. Moreover, xenon anaesthesia was associated with a lower risk for POD, a finding that has to be confirmed in larger studies. Clinical trial registration: ClinicalTrials.gov (NCT01757106) and EudraCT (2012-002316-12).
Editor's key points
• The noble gas xenon is an anaesthetic agent with a favourable haemodynamic profile.
• The authors performed a non-inferiority study comparing xenon with sevoflurane anaesthesia among cardiac surgery patients.
• Non-inferiority was demonstrated with regard to vasopressor requirements.
• Xenon was associated with lower vasopressor requirements and also less postoperative delirium.
In non-cardiac surgery, the noble gas xenon has been reported to produce only minimal haemodynamic side effects when compared with other anaesthetics, even in high-risk cardiovascular patients. 1 2 These observations were confirmed by multicentre randomized controlled trials in which xenon was compared with isoflurane and was found to slightly decrease heart rate and to preserve or moderately increase arterial pressures. 3 4 Such haemodynamic effects may result in an overall improvement of the balance between myocardial oxygen delivery and consumption. Moreover, xenon is virtually devoid of negative inotropic effects, 5 preserves myocardial blood flow, 6 improves recovery from post-ischaemic contractile dysfunction, 7 and limits adverse remodelling after perioperative myocardial infarction. 8 As the course of off-pump coronary artery bypass (OPCAB) surgery entails significant haemodynamic alterations, OPCAB patients carry a high-risk for perioperative myocardial ischaemia and perioperative haemodynamic instability. 9 This contributes to the development of perioperative organ injury, including myocardial infarction, stroke, and acute kidney injury. 10 11 The favourable haemodynamic profile of xenon anaesthesia and its organ-protective properties could render xenon an attractive option for patients undergoing OPCAB surgery. Until now, experience with xenon in cardiac anaesthesia has been limited and was obtained in surgical procedures using cardiopulmonary bypass. 12 13 To the best of our knowledge, the present investigation is the first clinical study of xenon in patients undergoing OPCAB surgery. We hypothesized that xenon anaesthesia during OPCAB surgery is non-inferior to sevoflurane in terms of haemodynamic stability (as reflected by vasopressor requirements). Secondary aims of the study included the assessment of various perioperative safety parameters.
Methods

Study design and population
The study was approved by the local ethics committee (s54450, Commissie Medische Ethiek van de Universitaire Ziekenhuizen KU Leuven) and by the Federal Agency for Medicines and Health Products, Brussels, Belgium (reference FAGG/R&D/WHH/mm 445642). It was registered at ClinicalTrials.gov (NCT01757106), the European Medicines Agency (EudraCT 2012-002316-12) and is reported according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines (see Supplementary material, supplementary document). 14 After obtaining written informed consent, 42 patients scheduled for elective OPCAB surgery were enrolled in this prospective, single-centre, randomized, singleblinded, controlled pilot study. Patients were randomized to receive general anaesthesia with xenon or sevoflurane. Randomization was performed using a software-generated allocation sequence. Selection bias was avoided by a masked randomization procedure using sealed, opaque, sequentially numbered envelopes that were opened only upon arrival of the patient in the operating room (OR). Two investigator types conducted the study: investigator I completed patient enrolment and postoperative follow-ups and was, like the patient, blinded to the study group. 15 Investigator II performed randomization and general anaesthesia for OPCAB surgery and could not be blinded due to the administration of the anaesthetic via a dedicated anaesthesia machine and the mandatory monitoring of anaesthetic concentrations. Patients could be included if they were >18 years of age and scheduled for elective OPCAB surgery. Exclusion criteria were as follows: lack of informed consent; chronic obstructive pulmonary disease (COPD) ; depression (as assessed by the Geriatric Depression Scale) 18 ;
history of stroke with residuals; hypersensitivity to the study medication; patients at risk for malignant hyperthermia; uncooperativeness or legal incapacity.
Anaesthesia and intervention
Patients received perioperative care according to our institutional routine. 19 All patients were premedicated with sublingual lorazepam 0.03 mg kg −1 an hour before surgery. In the OR, standard cardiorespiratory monitoring was instituted, including electrocardiogram pulse oximeter and invasive registration of arterial blood pressure (IntelliVue MX800 patient monitor, Philips, Boeblingen, Germany). In addition, the bispectral index (BIS) (Covidien, Dublin, Ireland) and regional cerebral oxygen saturation (rSO 2 ) (FORE-SIGHT ® , Casmed, Branford, CT, USA) were continuously recorded. General anaesthesia was induced with propofol (0.5-1 mg kg ). In both groups, intraoperative analgesia was achieved with a sufentanil infusion (0.5-1 µg kg 
Surgical technique
All patients underwent total arterial revascularization using the 'no touch aorta technique' (for further details, see the Supplementary material, supplementary document). 19 
Postoperative treatment and monitoring
At end of surgery, the investigational treatment was stopped and patients were transferred to the intensive care unit (ICU), where analgosedation was maintained with propofol and piritramide. Tracheal extubation and discharge from the ICU were performed when standard criteria were fulfilled. One hour after ICU admission and at the first postoperative morning, cardiopulmonary parameters, a 12-lead ECG, and laboratory parameters were noted. The Simplified Acute Physiology Score (SAPS) II 21 and the Sequential Organ Failure Assessment (SOFA) score 22 were determined once within 24 h of ICU admission. Subsequently patients were visited daily until postoperative day 5 for the assessment of vital parameters and performance of the CAM for the ICU (CAM-ICU), modified Brice questionnaire 23 ( postoperative day 3), and MMSE ( postoperative day 3). Analogous visits took place on postoperative day 7 and on the day before discharge. Concomitant medications, adverse events (AEs), and serious adverse events (SAE) were recorded in all study visits. Six months after surgery the patients' family practitioners were contacted for the assessment of long-term outcome (see below).
Study outcomes
Primary outcome was the dose of noradrenaline that was required intraoperatively to achieve the predefined haemodynamic goals (as mentioned above). Secondary outcomes included intraand postoperative safety criteria:
• The incidence of major adverse cardiac and cerebral events (MACCEs) within 6 months after surgery, i.e. death from any cause, myocardial infarction (defined as the occurrence of a new Q wave in addition to an increase in troponin T exceeding the 99th percentile of the upper reference level in the early postoperative period or any episode of chest pain with a typical increase of cardiac enzyme), requirement of surgical revisions at the coronary vessels, postoperative coronary angioplasty, and stroke.
• Any cerebrovascular accident not included in the MACCEs (transient ischaemic attacks, reversible ischaemic neurologic deficit).
• Incidence of serious adverse events (SAEs) and suspected unexpected serious adverse reactions not included above.
According to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 24 an AE is defined as 'any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.' An SAE is defined as 'any AE that was life threatening, resulted in death, required patient's rehospitalisation and/or prolongation of existing hospitalisation, or resulted in patient's disability'.
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• Requirements for blood ( product) transfusion.
• Any complication occurring in the early postoperative period and not mentioned above (i.e. wound infection, bleeding).
In addition, secondary outcomes included
• The occurrence of postoperative delirium (POD). During the ICU stay, patients were assessed daily for the presence of POD by trained research nurses (blinded to the group assignment) using the CAM-ICU. Patients with a Richmond Agitation Sedation Scale (RASS) <−3 were considered to be unconscious and not evaluable for POD. After transferal to the ward, patients were also screened daily for the presence of POD, until postoperative day 9, using the CAM.
• Postoperative renal function [as assessed by the Risk, Injury, and Failure; and Loss; and End-stage kidney disease (RIFLE) criteria] 25 • Duration of postoperative ICU and hospital stay.
• Severity of postoperative critical illness as indicated by the SAPS II and the SOFA score.
• Intraoperative cardiorespiratory profile.
• Intraoperative use of inotropes and other vasoactive medication.
• Intraoperative cerebral oxygen saturation.
• Inflammatory markers as assessed by serum levels of interleukin-6 (IL-6) and IL-10 and tumour necrosis factor alpha (TNF-α) measured at T1, T6, and postoperative day 1.
• Perioperative and postoperative serum levels of S-100β and plasma levels of erythropoietin (EPO).
Laboratory data
As mentioned above, arterial blood samples at T1, T6 and postoperative day 1 were obtained for the determination of myocardial ischaemia markers, serum levels of cytokines and TNF-α, S-100β and plasma levels of EPO. Further details are described in the Supplementary material (supplementary document).
Statistical analysis
This study aims to assess whether xenon is non-inferior to equipotent sevoflurane concentrations with respect to the noradrenaline doses required to achieve the predefined haemodynamic goals. All analyses were performed on an intention-to-treat basis. The sample size was determined to show non-inferiority of xenon vs sevoflurane for the consumption of intraoperative noradrenaline assuming equal consumption levels in both groups. The limit of the region of non-inferiority is set at a 20% higher consumption. Note that this implies 1.2 as an upper limit for the ratio (xenon:sevoflurane) of the (geometric) means. Assuming a coefficient of variation (CV) equal to 0.2 (based on unpublished observations in patients undergoing OPCAB surgery in our institution), 20 patients per group were needed to have at least 80% power to show non-inferiority, based on a one-sided non-inferiority t-test for log-normal data with α=2.5%. For each group, 21 patients were included to compensate for possible dropouts.
Statistical analysis was performed with a commercially available software package (SPSS Statistics Desktop, version 21.0.0 for Mac OS, IBM, Armonk, NY, USA). For the statistical analysis of the primary outcome, a 95% confidence interval (CI) was constructed for the ratio of the (geometric) mean comparing the intraoperative noradrenaline consumption of xenon with sevoflurane. For a single patient in the xenon group that did not require noradrenaline at all, the minimal observed consumption was assumed to allow the necessary log transformation. Other continuous variables were compared between groups using the Mann-Whitney U test. Differences in proportions were analysed using the Fisher's exact test. Results of repeated measurements were analysed using Friedman's analysis of variance with the within-factor time (given the non-normal distribution of our data). Vertical and horizontal pairwise contrasts were analysed using the Mann-Whitney U and Wilcoxon test, respectively, with the Bonferroni adjustment for multiple comparisons. 26 27 In addition, as a quantification of the effect size, the discriminative ability and 95% CI was calculated using SAS System for Windows, version 9.2, SAS Institute, Cary, NC, USA). This quantification is known as the c-index, with 0.5 and 1 referring to random prediction and perfect discrimination, respectively. Freedom from POD was analysed with the Kaplan-Meier method and compared between the two groups using the log-rank (Mantel-Cox) test. 28 In addition, the hazard ratio for the development of POD in both groups was also reported. In all cases, a P-value <0.05 was considered to be statistically significant.
Results
Preoperative assessment and intraoperative data
From December 2012 to July 2013, 79 patients scheduled for elective OPCAB surgery were screened. A total of 42 patients were enrolled and randomized to receive general anaesthesia with either xenon (n=21) or sevoflurane (n=21) (Fig. 1) . Baseline characteristics and demographic data were similar in both groups (Table 1) .
No patient was lost to follow-up. Groups did not differ with respect to procedure-related times and the number of performed grafts (Table 2 ). Both groups received equal haemodynamic therapy as indicated by the intraoperative fluid balance, the use of anti-hypertensive drugs and inotropes (Table 2) .
Intraoperative vasopressor requirements
Xenon was non-inferior to sevoflurane with respect to vasopressor need (Fig. 2) . The geometric mean level for noradrenaline consumption in the xenon and sevoflurane groups was 428 (95% CI 312, 588) and 1702 (1267, 2285) µg, respectively. The resulting ratio equals 0.252 (95% CI 0.165, 0.383), with the upper limit of the CI clearly falling in the predefined non-inferiority region. The current result even indicates the superiority of xenon vs sevoflurane regarding intraoperative noradrenaline consumption (P<0.0001 based on a two-sided independent t-test for log-normal data as well as based on the Mann-Whitney U test). Likewise, less phenylephrine was needed in the xenon patients (Table 2) .
Intra-and postoperative safety data
The incidence of intraoperative AEs and SAEs was comparable in both groups (Table 2) . Similarly, the incidence of postoperative AEs and SAEs was also comparable in both groups (Table 3 ). In the sevoflurane group, significantly more patients developed POD during the observation period (Fig. 3) . No differences were found concerning the duration of postoperative mechanical ventilation and (ICU) hospital length of stay in both groups ( Table 3 ). The sevoflurane group had less blood loss at postoperative day 1 (Table 3 ) compared with the xenon group. Despite that difference, the need for transfusion was similar in both groups.
Anaesthetic depth
Neither clinical signs (heart rate, blood pressure, sweating, etc.) nor BIS values ( Table S1 ). Regional cerebral oxygen saturation (Table 2) , other haemodynamic variables, respiratory parameters, and results obtained from blood gas analysis were comparable in both groups (for details, see Supplementary material, Table S1 ).
Laboratory findings
The perioperative time course of S-100β and plasma levels of EPO showed a comparable postoperative increase in both groups (Supplementary material, Fig. S2 ). Biochemical markers of perioperative myocardial ischaemia were similar in both groups (Supplementary material, Table S2 ). In addition, the time course of inflammatory parameters showed no statistical differences between the two groups except for IL-10, which was significantly higher in the sevoflurane group at postoperative day 1 (Supplementary material, Table S2 ). TNF-α was detectable in only one patient in each group.
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Discussion
In the present study we found that the use of xenon in patients undergoing OPCAB surgery may facilitate intraoperative haemodynamic management by reducing intraoperative vasopressor requirements and better preserving of the mean arterial blood pressure. In addition, we observed a lower occurrence of POD in patients anaesthetized with xenon. The latter finding most probably does not prove a causal relationship, but warrants further investigation in larger and adequately powered randomized controlled trials.
Both in cardiac and non-cardiac surgery, even brief periods of intraoperative hypotension have been repeatedly shown to represent an important risk factor for the development of postoperative morbidity and mortality. 29 Due to frequent intraoperative manipulations and temporary enucleation of the heart, patients undergoing OPCAB surgery are at particular risk for intraoperative arterial hypotension that may result in perioperative organ injury, including myocardial ischaemia, acute kidney injury, and stroke. 9 11 Therefore maintenance of haemodynamic stability by the avoidance and appropriate treatment of arterial hypotension is a pivotal goal of haemodynamic management during OPCAB surgery. It is well known that xenon causes less cardiovascular deterioration than conventionally used anaesthetics. 1 4 10 The efficacy of xenon anaesthesia in OPCAB surgery could be most explicitly tested by comparing the number of hypotensive episodes and the degree of hypotension with the control group. However, such a direct quantification of hypotensive episodes would be unjustifiable since hypotension has to be immediately corrected by the administration of vasopressors to maintain perfusion pressures. Consequently we assessed haemodynamic stability by the average noradrenaline doses that, after achieving normovolaemia, had to be administered to maintain the predefined intraoperative haemodynamic goals, including a MAP ≥70 mm Hg. 9 This approach has been recently described and uses vasopressor doses as a surrogate and quantitative marker for hypotension. 30 In our patients, the doses of intraoperative vasopressors were significantly reduced by the use of xenon as a general anaesthetic. In addition, xenon patients had significantly higher intraoperative MAPs compared with the sevoflurane group. It is certainly debatable whether a reduction in vasopressor need can be considered to be a genuine improvement that justifies the considerable costs associated with xenon anaesthesia. On the one hand, vasopressor dependency in cardiac surgical patients has been proven to be an independent risk factor for postoperative morbidity. 31 Moreover, a reduction in vasopressor requirements facilitates the haemodynamic management of these high-risk procedures. On the other hand, our findings of less vasopressor use and haemodynamic non-inferiority could not be translated into an improvement of the majority of outcome parameters. Instead, our finding that the use of xenon was associated with comparable incidences of intra-and postoperative adverse events suggests that xenon can be considered as equally safe as the established anaesthetic sevoflurane and confirms our recent findings in on-pump coronary artery bypass grafting. 13 This conclusion is also supported by our results that patients in the xenon group showed a similar extent of perioperative myocardial injury as assessed by troponin T and creatine kinase MB. In murine models, xenon has been repeatedly demonstrated to exert potent nephroprotective effects in the setting of renal ischaemia/reperfusion injury, in part due to an increased production of hypoxia-inducible factor 1α and its downstream effector EPO in the renal cortex. 32 These observations have led to the recent decision of the World Anti-Doping Agency to add xenon gas to the list of banned substances in sports. 33 In our patients, the use of xenon did not reduce the incidence of acute kidney injury (AKI). This may be attributed to a lack of statistical power. In addition, the incidence of AKI in our study was much lower than previously reported. 11 Moreover, ischaemia/reperfusion injury is most probably not the sole trigger of AKI in OPCAB surgery. Interestingly, postoperative plasma levels of EPO in xenon patients did not exceed those measured in sevoflurane patients. On the basis of this observation, we suggest that postoperative anaemia was the primordial trigger of EPO release in our patients. POD is frequently observed after cardiac surgery, with incidences ranging from 20 to 80%. 34 It is associated with shortterm complications such as increases in mortality, morbidity, costs, and length of stay, but can also cause long-term sequelae such as persistent cognitive deficits, loss of independence, and increased mortality for up to 2 years. 35 Notably, xenon has 27 (5) 25 ( (14) 0.232 MI within 90 days, n (%)
3 (14) 4 (19) 1.000 Angina at rest, n (%)
5 (24) 3 (14) 0.697 Arterial hypertension, n (%)
19 (90) 16 (76) 0.410 COPD GOLD I-II, n (%)
2 (10) 1 (5) 1.000 Diabetes mellitus, n (%)
4 (19) 2 (10) 0.663 History of TIA/CVA, n (%) 1 (5) 1 (5) 1.000 eCcr, median (IQR), ml min Xenon for OPCAB surgery | 555 been shown to offer neuroprotection in different in vitro and in vivo models, including post-cardiac surgery neurocognitive dysfunction. 36 Neuroprotection by xenon is most likely achieved by antagonism at the N-methyl-D-aspartate subtype of the glutamate receptor, 37 preservation of cerebral flow-metabolism coupling, 38 enhanced synthesis of prosurvival proteins, and suppression of apoptosis. 39 Interestingly, we found xenon significantly reduced the occurrence of POD in our patients. This observation most probably does not reflect a causal relationship. Patients in the xenon group showed a comparable perioperative release of inflammatory cytokines (known to trigger POD) 40 and also S-100β, which is a reliable non-specific marker for the integrity of the blood-brain barrier. 41 Given the small sample size, this finding should be interpreted with caution, but it certainly warrants testing in adequately powered clinical trials with POD incidence as the primary outcome.
Limitations
We acknowledge that our study suffers from several limitations. First, we applied rather strict exclusion criteria, thereby avoiding the inclusion of patients with severe co-morbidities and obviating potential confounders. We consider this approach to be justified since limited data are available concerning the use of xenon in patients with an ASA score >II with coronary heart disease. Second, the primary endpoint of this study was not assessed by blinded investigators. However, the investigators who performed the xenon anaesthesia had to adhere to a strict haemodynamic treatment protocol in order to ensure equal management in both groups. The decreased need for vasopressors in the xenon group can therefore not be entirely attributed to differences in haemodynamic management. Moreover, all postoperative outcomes were assessed by investigators blinded to the group affiliation. Third, xenon was only administered in the intraoperative period. Any potential advantages with respect to faster recovery after xenon were probably masked by postoperative sedation in the ICU. Fourth, we acknowledge that the CV underlying the sample size estimation is much smaller than the CV that was eventually observed. The sample size estimation was based on the noradrenaline consumption of 10 pilot patients that underwent OPCAB surgery at our institute and were exclusively anaesthetized with sevoflurane. While the reasons for the discrepancy between the anticipated and observed CV are unclear, this should not invalidate our findings. Note that with the obtained CV (which was considerably higher than the one used for the sample size calculation), the current study would not have 80% power to show non-inferiority under the scenario of no difference. However, differences in norepinephrine consumption were highly significant. Last, acknowledging that the study is only powered for a single primary outcome, the majority of observations with respect to secondary outcomes are purely exploratory and should be interpreted with caution. Xenon for OPCAB surgery | 557
In conclusion, we found that the use of xenon may facilitate intraoperative haemodynamic management in patients undergoing OPCAB surgery. Compared with sevoflurane, xenon reduces intraoperative vasopressor requirements and better preserves mean arterial blood pressure. In addition, we observed comparable incidences of intra-and postoperative adverse events for xenon and sevoflurane. In the sevoflurane group, significantly more patients developed POD during the observation period. The latter result certainly does not prove a causal relationship but warrants further investigation in an adequately powered randomized controlled clinical trial. 
